Trial Profile
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 27 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 Initial booster data and final data from the study, presented in a Valneva media release.
- 02 Aug 2018 According to a Valneva media release, based on the results of the Interim analysis, the Company amended the protocol to include a booster evaluation at one year post initial vaccination, in approximately 60 subjects. Results are expected in the first half of 2019.